Objective： To investigate the effect of Chinese medicine （CM） on survival of patients with stage Ⅱ and Ⅲ colorectal cancer （CRC）. Methods： A total of 295 patients who received chemotherapy were assigned to Gro...Objective： To investigate the effect of Chinese medicine （CM） on survival of patients with stage Ⅱ and Ⅲ colorectal cancer （CRC）. Methods： A total of 295 patients who received chemotherapy were assigned to Group 1. The other 171 patients received the same chemotherapy treatment combined with the usage of CM Jianpi Jiedu Formula （健脾解毒方, JPJD） for more than 3 months （Group 2）. Patients＇ survival time, relapse and metastasis, and cause of death were observed. Cox proportional hazard regression models were established for the analysis of the effect of independent factors on the survival prognosis of patients with CRC. Results： The survival rate of patients in Group 2 was higher than that of Group 1 （P〈0.05）. Compared with Group 1, the mean survival time was prolonged by 5.594 months and the median survival time was prolonged by 6 months in Group 2 （P=0.004）. Cox regression analysis indicated that CM combined with chemotherapy provided significant protective effect, as observed with the improvements in the survival rates of CRC patients （P〈0.01）. Conclusion： CM can improve the survival rate in patients with stage Ⅱ and Ⅲ CRC.展开更多
基金Supported by the National Natural Science Foundation of China(No.81273722)
文摘Objective： To investigate the effect of Chinese medicine （CM） on survival of patients with stage Ⅱ and Ⅲ colorectal cancer （CRC）. Methods： A total of 295 patients who received chemotherapy were assigned to Group 1. The other 171 patients received the same chemotherapy treatment combined with the usage of CM Jianpi Jiedu Formula （健脾解毒方, JPJD） for more than 3 months （Group 2）. Patients＇ survival time, relapse and metastasis, and cause of death were observed. Cox proportional hazard regression models were established for the analysis of the effect of independent factors on the survival prognosis of patients with CRC. Results： The survival rate of patients in Group 2 was higher than that of Group 1 （P〈0.05）. Compared with Group 1, the mean survival time was prolonged by 5.594 months and the median survival time was prolonged by 6 months in Group 2 （P=0.004）. Cox regression analysis indicated that CM combined with chemotherapy provided significant protective effect, as observed with the improvements in the survival rates of CRC patients （P〈0.01）. Conclusion： CM can improve the survival rate in patients with stage Ⅱ and Ⅲ CRC.
文摘目的:探讨健脾化瘀解毒方通过抑制细胞焦亡防治胃癌前病变的作用机制。方法:构建胃癌前病变小鼠模型和细胞焦亡模型,将小鼠随机分为空白组,模型组,健脾化瘀解毒方高剂量组(15 g/kg)、低剂量组(7.5 g/kg)和维酶素组(0.2 g/kg),每组10只。分别进行干预后,观察小鼠胃黏膜组织病理变化及焦亡相关分子表达情况。细胞分为空白组、模型组和中药组,空白组与模型组给予空白血清,中药组给予含药血清干预后,除空白组外先后予以LPS、ATP处理。观察焦亡相关分子表达情况。结果:与空白组比较,模型组小鼠胃黏膜NLRP3、GSDMD、HMGB1表达显著升高(P<0.01),健脾化瘀解毒方高、低剂量组可显著降低其表达(P<0.01)。与空白组比较,模型组细胞焦亡关键分子NLRP3、GSDMD、Caspase-1 mRNA和蛋白表达水平升高(P<0.01,P<0.05),I L-1β、I L-18 m R NA表达水平显著升高(P<0.01),中药组可显著降低其表达水平(P<0.01,P<0.05)。结论:健脾化瘀解毒方可通过抑制细胞焦亡防治胃癌前病变。
